impel neuropharma, inc., is a privately-held, seattle-based company devoted to creating life-changing, innovative therapies for central nervous system (cns) diseases. impel's products are based on a novel nasal drug delivery platform, the pod™ device, that administers drug to the upper nasal cavity in a consistent and predictable manner. impel neuropharma is currently investigating inp104 (pod™ dhe) for acute migraine headache, inp103 (pod™ levodopa) for parkinson's disease, inp105 (pod™ olanzapine) for agitation in schizophrenia and bipolar disorders as well as inp102 (pod™ insulin) for alzheimer's disease in an nih funded trial. impel neuropharma's proprietary pod™ device enables small and large molecule drugs to be administered using a cost-effective, disposable, non-invasive intranasal drug delivery device. to learn more about impel neuropharma, please visit our website at http://impelnp.com.
Company profile
Ticker
IMPLQ, IMPL
Exchange
Website
CEO
Michael Hite
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IMPEL NEUROPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
Impel NeuroPharma Australia PTY LTD ...
IRS number
263058238
IMPLQ stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
26 Mar 24
8-K
Amendments to Articles of Incorporation or Bylaws
12 Mar 24
EFFECT
Notice of effectiveness
16 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
POS AM
Prospectus update (post-effective amendment)
14 Feb 24
8-K
Entry into a Material Definitive Agreement
14 Feb 24
8-K
Other Events
2 Jan 24
25-NSE
Exchange delisting
27 Dec 23
Transcripts
IMPLQ
Earnings call transcript
2023 Q1
12 May 23
IMPLQ
Earnings call transcript
2022 Q4
24 Mar 23
IMPLQ
Earnings call transcript
2022 Q3
14 Nov 22
IMPLQ
Earnings call transcript
2022 Q2
15 Aug 22
IMPLQ
Earnings call transcript
2022 Q1
17 May 22
IMPLQ
Earnings call transcript
2021 Q4
24 Mar 22
IMPLQ
Earnings call transcript
2021 Q3
15 Nov 21
IMPLQ
Earnings call transcript
2021 Q2
17 Aug 21
Latest ownership filings
3
Brandon D Smith
26 Dec 23
4
Change in insider ownership
19 Dec 23
4
Asset Management ULC Brookfield
4 Dec 23
4
Change in insider ownership
4 Dec 23
4
Change in insider ownership
4 Dec 23
SC 13D/A
Oaktree Capital Group, LLC
4 Dec 23
3
Asset Management ULC Brookfield
20 Nov 23
3
Initial statement of insider ownership
20 Nov 23
3
Initial statement of insider ownership
20 Nov 23
SC 13D/A
Oaktree Capital Group, LLC
15 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.74 mm | 4.74 mm | 4.74 mm | 4.74 mm | 4.74 mm | 4.74 mm |
Cash burn (monthly) | 3.47 mm | 6.25 mm | 4.60 mm | 6.92 mm | 5.51 mm | 6.59 mm |
Cash used (since last report) | 20.78 mm | 37.39 mm | 27.55 mm | 41.40 mm | 32.96 mm | 39.44 mm |
Cash remaining | -16.04 mm | -32.65 mm | -22.81 mm | -36.66 mm | -28.22 mm | -34.70 mm |
Runway (months of cash) | -4.6 | -5.2 | -5.0 | -5.3 | -5.1 | -5.3 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 5 |
Closed positions | 6 |
Increased positions | 4 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 7.52 bn |
Total shares | 30.03 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Kohlberg Kravis Roberts & Co. | 4.14 mm | $1.78 bn |
KKR Iris Investors | 3.80 mm | $57.23 mm |
NVP Associates | 3.08 mm | $1.32 bn |
5AM Venture Management | 2.88 mm | $1.24 bn |
Vivo Capital VIII | 2.88 mm | $43.42 mm |
Vivo Capital | 2.88 mm | $1.24 bn |
venBio Global Strategic Fund II | 2.76 mm | $41.54 mm |
venBio Partners | 2.76 mm | $1.19 bn |
5AM Ventures V | 2.31 mm | $34.76 mm |
OAK-PA Oaktree Capital | 1.21 mm | $477.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Dec 23 | Vivo Capital VIII | Common Stock | Sell | Dispose S | Yes | No | 0.08 | 28,632 | 2.29 k | 280,294 |
19 Dec 23 | Vivo Capital VIII | Common Stock | Sell | Dispose S | Yes | No | 0.08 | 208,657 | 16.69 k | 2,029,495 |
18 Dec 23 | Vivo Capital VIII | Common Stock | Sell | Dispose S | Yes | No | 0.11 | 28,682 | 3.16 k | 308,926 |
18 Dec 23 | Vivo Capital VIII | Common Stock | Sell | Dispose S | Yes | No | 0.11 | 209,029 | 22.99 k | 2,238,152 |
15 Dec 23 | Vivo Capital VIII | Common Stock | Sell | Dispose S | Yes | No | 0.29 | 12,066 | 3.50 k | 337,608 |
15 Dec 23 | Vivo Capital VIII | Common Stock | Sell | Dispose S | Yes | No | 0.29 | 87,934 | 25.50 k | 2,447,181 |
30 Nov 23 | Oaktree-TCDRS Strategic Credit | Warrants Common Stock | Other | Acquire J | Yes | No | 0.01 | 445,294 | 4.45 k | 3,117,057 |
30 Nov 23 | Oaktree GCP Fund Delaware | Warrants Common Stock | Other | Acquire J | Yes | No | 0.01 | 445,294 | 4.45 k | 3,117,057 |
30 Nov 23 | Brookfield Corporation - Ordinary Shares | Warrants Common Stock | Other | Acquire J | Yes | No | 0.01 | 445,294 | 4.45 k | 3,117,057 |